Síndrome de Parkinson: Revisión bibliográfica y actualización
DOI:
https://doi.org/10.26820/recimundo/4.(4).octubre.2020.270-281Palabras clave:
Parkinson, Fisiopatología, Diagnostico, TratamientosResumen
El síndrome de Parkinson (SP), es un desorden neurodegenerativo causado por una pérdida progresiva de neuronas dopaminergicas en la Sustancia Nigra pars compacta (SNpc). SP ocasiona ciertas anomalías motoras como por ejemplo temblor en reposo y rigidez muscular. Con un buen diagnóstico y en base a su fisiopatología podemos conseguir mejores resultados dando un tratamiento tanto clínico como quirúrgicos según corresponda. En la actualidad, debido a nuevas formas de tratamiento para el SP, debemos conocer las bases fisiopatológicas del mismo, para posterior analizar de una manera más estricta la terapéutica a seguir. El objetivo de esta revisión es integrar y plasmar las teorías fundamentales y actuales relacionadas al Síndrome de Parkinson. El estudio se realizó mediante un búsqueda minuciosa y análisis de artículos indexados en las bases de información médicas: Pubmed, Pubmed Central, Medline, por lo que es un estudio tipo documental, bibliográfico. Es fundamental tener un estudio bibliográfico, en el cual se pueda comprender claramente la fisiopatología y así, poder diferenciar las nuevas tendencias en cuanto al tratamiento clínico o quirúrgico que puedan tener los pacientes con (SP).Descargas
Citas
Radhakrishnan DM, Goyal V. Parkinson's disease: A review.Neurol India 2018;66:26-35
Adams RD, Victor MD, Allan MD. In: ED McGraw-Hill interamericana, editor. Principios de Neurología. Sexta edición ed. México: 2000. p. 925-31.
GBD 2016 Parkinson Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17: 939-53
Palacios N. Air pollution and Parkinson's disease-evidence and future directions. Reviews on environmental health. Rev Environ Health 2017; 32 (4): 303-13
Costa P, Zabetian C, Ching S, Agarwa P, Yearout D, Checkoway H. Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels
in Parkinson disease. J Neural Transm 2016; 123:1319-30.
Juan M, Paola M, Lisbeth A. Elba I, Diana M, (2017). Prevalencia de la Enfermedad de Parkinson: Estudio Puerta-Puerta en la Provincia de Manabí-Ecuador. Prevalence of Parkinson's Disease: Door-to-door Study in Manabi-Ecuador. Revista ecuatoriana de neurologia; 1-3
Federico E. Enfermedad de Parkinson y trastornos relacionados. Argentina: 1998.
Lowe J, Lennox G, Leigh PN. In: Greenfield's Neuropathology, editor. Disorders of mevement and system degerations. sexta edición ed. Londres: 1996. p. 28 366.
Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24 (2): 197-211.
Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318 (1): 121-34.
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysio-logic and clinical implications. N Engl J Med 1988; 318 (14): 876-80
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neu-rosci 1989; 12 (10): 366-75.
Albin RL, Young AB, Penney JB. The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995; 18 (2): 63-4.
Naito A, Kita H. The cortico-nigral projection in the rat: an anterograde tracing study with biotin-ylated dextran amine. Brain Res 1994 Feb 21; 637 (1-2): 317-22.
Fogelson N, Pogosyan A, Kuhn AA, Kupsch A, van BG, Speelman H, et al. Reciprocal interactions between oscillatory activities of different frequencies in the subthalamic region of patients with Parkinson's disease. Eur J Neurosci 2005; 22 (1): 257-66.
Pan MK, Tai CH, Kuo CC. Parkinson's disease and cortico-Basal Ganglia circuits. Acta Neurol Taiwan 2010; 19 (3): 209-18.
Smith Y, Parent A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res 1988; 453 (12): 353-6.
Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992; 42 (4): 733-8.
Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998; 44 (3 Suppl 1): S175-S188.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74.
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. The Parkinson's Study Group. Neurology 1990;40, 1529-34.
Lim SY, Lang AE. The nonmotor symptoms of Parkinson's disease-An overview. Mov Disord 2010;25(Suppl 1): S123-S130.
Aarsland D, Beyer MK, Kurz MW. Dementia in Parkinson's disease. Curr Op Neurol 2008;21:676-82.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society. 2015;30(12):1591-601.
Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson's disease: A systematic review and meta- analysis. Neurology 2016 86:566-76.
Politis M. Neuroimaging in Parkinson's disease: From research setting to clinical practice. Nat Rev Neurol 2014;10:708-22
Ibrahim N, Kusmirek J, Struck AF, Floberg JM, Perlman SB, Gallagher C, et al. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. Am J Nucl Med Mol Imaging 2016;6:102-9.
Chen-Plotkin AS. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 2014;84:594-607.
Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. European journal of neurology. 2013;20(1): 5 -15.
Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, et al. Priorities in Parkinson’s disease research. Nature reviews Drug discovery. 2011;10(5):377-93
Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17
Poewe W., Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord 2015;30:114-20.
Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26:S2-41.
Connolly B, Lang AE. Pharmacological treatment of Parkinson's disease: A review. JAMA 2014;311:1670-83.
Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's's disease: Review of recent trials. Mov Disord 2013;28:131-44
Seppi, K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26:S42-S80.
Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics 2014;11:78-91.
Zhou, ZH, Wu YF, Wang X, Hahn YZ. The c-Abl inhibitor in Parkinson's disease. Neurol Sci 2017;38:547-52.
Martinez-Fernandez, R., Gasca Salas, C., Sanchez Ferro, A., Obeso, J., 2016. Actualizaciónen la enfermedad de parkinson. Rev. Med. Clin. Condes 27 (3), 363–379.
Lozano CS, Tam J, Lozano AM (2018) The changing landscape of surgery for Parkinson’s disease. Mov Disord 33, 36-47.
Hassler R, Riechert T (1954) [Indications and localization of stereotactic brain operations]. Nervenarzt 25, 441-447.
Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ, Jr., Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ, CSP 468 Study Group (2010) Pallidal versus subthalamic deepbrain stimulation for Parkinson’s disease.N Engl J Med 362, 2077-2091.
Martinez-Fernandez R, Rodriguez-Rojas R, Del Alamo M, Hernandez-Fernandez F, Pineda-Pardo JA, Dileone M, Alonso-Frech F, Foffani G, Obeso I, Gasca-Salas C, de Luis-Pastor E, Vela L, Obeso JA (2018) Focused ultrasound subthalamotomy in patients with asymmetric Parkinson’s disease: A pilot study. Lancet Neurol 17, 54-63.
Bond AE, Shah BB, Huss DS, Dallapiazza RF, Warren A, Harrison MB, Sperling SA, Wang XQ, Gwinn R, Witt J, Ro S, Elias WJ (2017) Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: A randomized clinical trial. JAMA Neurol 74, 1412-1418.
Lee, Darrin J. and Lozano, Andres M. ‘The Future of Surgical Treatments for Parkinson’s Disease’. 1 Jan. 2018 : S79 – S83.
